Hosseini, Iraj
Gadkar, Kapil
Stefanich, Eric
Li, Chi-Chung
Sun, Liping L.
Chu, Yu-Waye
Ramanujan, Saroja http://orcid.org/0000-0002-0909-9786
Funding for this research was provided by:
Genentech
Article History
Received: 31 July 2019
Accepted: 18 July 2020
First Online: 28 August 2020
Competing interests
: I.H., K.G., E.S., C.-C.L., and S.R. are all employees of Genentech Inc.; L.L.S. was an employee of Genentech at the time the studies were conducted and is currently an employee at Harpoon Therapeutics. Y.-W.C. was an employee of Genentech at the time the studies were conducted and is currently an employee at Fate Therapeutics. Genentech has filed patent applications related to TDBs, and is currently conducting clinical studies of the molecule mosunetuzumab. Genentech holds no stake in the molecule blinatumomab, which is a clinically-approved molecule for the treatment of ALL. Investigators may request materials from Genentech by submitting a request form at ExternalRef removed.